Abdulwasiu Ibrahim | Drug Discovery | Young Scientist Award

Posted on by ScienceFather

Mr. Abdulwasiu Ibrahim | Drug Discovery | Young Scientist Award

Research Fellow, Drosophila Research and Training Centre Nigeria

Abdulwasiu Ibrahim is a biochemist specializing in cancer biology, molecular biology, and bioinformatics. He is affiliated with the Department of Biochemistry, University of Ibadan, Nigeria. His expertise spans drug discovery, precision medicine, pharmacogenomics, and toxicogenomics. Proficient in computational biology, he applies computer-aided drug design, immunoinformatics, and biochemical analytics to research. His technical skills include gel electrophoresis, ELISA, PCR, and spectroscopy. He has a strong background in statistical analysis using GraphPad Prism and Microsoft Excel, with foundational knowledge of Python. He has extensive research experience in genetic profiling and biological drug delivery. Currently, he is a Research Fellow at the Drosophila Research and Training Centre and a Research Associate at the Institute of Bioinformatics and Molecular Therapeutics. He has received multiple conference fellowships and published several high-impact research papers. His work contributes to advancing cancer treatment and precision medicine using bioinformatics and molecular biology approaches.

Publication Profile

Oricd

🎓 Education

Master of Science in Biochemistry (Cancer Research and Molecular Biology) – University of Ibadan, Nigeria (2022–2024) Thesis: Interactive Toxicity of 2-Acetylaminoflourene and Diethylnitrosamine in Drosophila melanogaster. Bachelor of Science in Biochemistry (Second Class Upper-Honours) – Usmanu Danfodiyo University, Sokoto, Nigeria (2015–2019)
Thesis: Analgesic Activity of n-Hexane Extract of Castor Seed on Formalin-Induced Pain in Albino Rats.

💼 Experience

Research Fellow – Drosophila Research and Training Centre (2022–Present) Designed and conducted Drosophila experiments, supervised students, and managed lab operations.. Research Associate (Volunteer) – Institute of Bioinformatics and Molecular Therapeutics (2022–Present) Developed computational models for drug discovery, performed molecular docking, and trained interns. Post-Graduate Research Assistant – University of Ibadan (2022–2024) Conducted molecular analysis of cancer markers and supervised undergraduate projects. Research Assistant – Drosophila Laboratory, University of Ibadan (2021–2022) Taught students Drosophila research techniques and performed oxidative stress biomarker analysis. Undergraduate Research Assistant – Usmanu Danfodiyo University (2019–2020) Conducted phytochemical screening, biochemical analysis, and systematic reviews. Tutorial Teacher – Nigerian Society of Biochemistry Students (2019) Taught biochemistry, pharmacology, and molecular biology to undergraduate students.

🏆 Awards & Honors

Conference Fellowships: 11th & 10th Conference of the Nigerian Institute of Medical Research (NIMR) (2022, 2021) 2nd Drug Discovery Africa International Conference (DDA) (2022) 2nd Conference of Nigerian Bioinformatics and Genomics Network (NBGN) (2021) 7th Unibadan Conference of Basic Medical Sciences (2021). Virtual Chair Award – Midwest Drosophila Conference (2022). Pre-Conference Workshops: Genotyping with TaqMan and Real-Time PCR Bioinformatics and Genome-Wide Association Studies Summer School: Hands-on training in bioinformatics and drug discovery. Best Paper Presentation: Nigerian Society of Biochemistry and Molecular Biology Conference (2021) Recognized for contributions to Drosophila biomedical research and computational drug design.

🔍 Research Focus

Cancer Biology & Genomics: Investigating genetic markers and molecular pathways in cancer progression. Molecular Biology & Bioinformatics: Computational modeling of biomolecules and genome-wide association studies. Drug Discovery & Design: Using in silico techniques to identify potential drug candidates for cancer and neurodegenerative diseases. Precision Medicine & Genetic Profiling: Exploring personalized treatment approaches through pharmacogenomics. Pharmacogenomics & Toxicogenomics: Studying drug responses and toxic effects at the genetic level. Biological Drug Delivery: Developing targeted therapies using nanoformulations and bioactive compounds. Computational Biology: Expertise in homology modeling, molecular docking, virtual screening, and molecular dynamics simulations. Laboratory Techniques: Skilled in gel electrophoresis, ELISA, PCR, spectrophotometry, and tissue imaging.

Publication Top Notes

  • Computational Investigation of Polo-like Kinase 1 (PLK1): Inhibitive Potential of Benzimidazole-Carbonamide Derivatives for Cancer Treatment
    • Year: 2024
    • Authors: Ipinloju, N.; Balogun, T.A.; Ibrahim, A.; Adeyemo, M.A.; Esan, T.O.; Emmanuel, A.V.; Bello, K.A.; Omiyeniyi, G.D.; Oyeneyin, O.E.
    • Citation: Physical Chemistry Research
    • Link: DOI: 10.22036/pcr.2023.377616.2331

 

  • Identification of Phytochemicals with Inhibitory Potential Against Beta-lactamase Enzymes via Computer-aided Approach
    • Year: 2024
    • Authors: Nwokebu, G.C.; Adesina, A.B.; Isibor, C.N.; Aigbepue, S.A.; Egbo, C.C.; Pureaziba, N.; Isaac, O.O.; Owolade, A.J.-J.; Alabere, H.O.; Iwuagwu, M.O.
    • Citation: Bioorganic Chemistry
    • Link: DOI: 10.1016/j.bioorg.2024.107238

 

  • Insight into the Corrosion Inhibiting Potential and Anticancer Activity of 1-(4-methoxyphenyl)-5-methyl-N’-(2-oxoindolin-3-ylidene)-1H-1,2,3-triazole-4-carbohydrazide via Computational Approaches
    • Year: 2024
    • Authors: Oluwatoba Emmanuel Oyeneyin; Abdulwasiu Ibrahim; Nureni Ipinloju; Adeniyi John Ademoyegun; Nathanael Damilare Ojo
    • Citation: Journal of Biomolecular Structure and Dynamics
    • Link: DOI: 10.1080/07391102.2023.2260491

 

  • Plant-derived Extracellular Vesicles as Potential Smart Nano Drug Delivery Systems for Antioxidant Vitamins C and E in Alzheimer’s Disease
    • Year: 2024
    • Authors: Amina Jiyah; Suleiman Alhaji Muhammad; Abdulwasiu Ibrahim; Ibrahim Bulama; Abdullahi Ibrahim; Abdullahi Yahya Abbas; Mustapha Umar Imam; Yusuf Saidu; Lawal Suleiman Bilbis
    • Citation: Journal of Drug Delivery Science and Technology
    • Link: DOI: 10.1016/j.jddst.2024.105618

 

  • Identification of Potential Acetylcholinesterase (AChE) Inhibitors from Vitis Vinifera: A Case Study of Alzheimer’s Disease (AD)
    • Year: 2023
    • Authors: Sofela, S.O.; Ibrahim, A.; Bodun, D.S.; Nwankwo, D.O.; Mafimisebi, M.; Abdulrasheed, B.; Balogun, T.; Opeyemi, I.
    • Citation: Research Square
    • Link: DOI: 10.21203/rs.3.rs-3342491/v1

 

  • Quantum Evaluation and Therapeutic Activity of (E)-N-(4-methoxyphenyl)-2-(4-(3-oxo-3-phenylprop-1-en-1-yl) phenoxy)acetamide and Its Modified Derivatives Against EGFR and VEGFR-2 in the Treatment of Triple-negative Cancer via In Silico Approach
    • Year: 2023
    • Authors: Ipinloju, N.; Ibrahim, A.; da Costa, R.A.; Adigun, T.B.; Olubode, S.O.; Abayomi, K.J.; Aiyelabegan, A.O.; Esan, T.O.; Muhammad, S.A.; Oyeneyin, O.E.
    • Citation: Journal of Molecular Modeling
    • Link: DOI: 10.1007/s00894-023-05543-2

 

  • Discovery of Potential Phytochemicals from Carica Papaya Targeting BRCA-1 in Breast Cancer Treatment
    • Year: 2023
    • Authors: Abdulwasiu Ibrahim; Nureni Ipinloju; Abdulsamad Omotayo Aiyelabegan; Abdulbaki Adio Alfa-Ibrahim; Suleiman Alhaji Muhammad; Oluwatoba Emmanuel Oyeneyin
    • Citation: Applied Biochemistry and Biotechnology
    • Link: DOI: 10.1007/s12010-023-04473-2

 

  • Discovery of Small Molecule PARKIN Activator from Antipsychotic/Anti-neuropsychiatric Drugs as Therapeutics for PD: An In Silico Repurposing Approach
    • Year: 2023
    • Authors: Abdulwasiu Ibrahim; Nureni Ipinloju; Nkechi Hope Atasie; Rahmotallah Mosunmola Babalola; Suleiman Alhaji Muhammad; Oluwatoba Emmanuel Oyeneyin
    • Citation: Applied Biochemistry and Biotechnology
    • Link: DOI: 10.1007/s12010-023-04376-2

 

  • Computational Evaluation of Azadirachta Indica-Derived Bioactive Compounds as Potential Inhibitors of NLRP3 in the Treatment of Alzheimer’s Disease
    • Year: 2023
    • Authors: Ishabiyi FO; Ogidi J; Olukade BA; Amorha CC; El-Sharkawy LY; Okolo CC; Adeniyi TM; Atasie NH; Ibrahim A.; Balogun TA
    • Citation: Journal of Alzheimer’s Disease (JAD)
    • Link: DOI: 10.3233/jad-221020

 

  • Discovery of Small Molecule PARKIN Activator as Therapeutics for PD: An In-silico Repurposing Approach
    • Year: 2022
    • Authors: Abdulwasiu Ibrahim; Nureni Ipinloju; Suleiman Alhaji Muhammad; Oluwatoba Emmanuel Oyeneyin; Nkechi Hope Atasie
    • Citation: Preprint
    • Link: DOI: 10.21203/rs.3.rs-2035291/v1

 

  • Antioxidant-Rich Nutraceutical as a Therapeutic Strategy for Sickle Cell Disease

 

Nozuko Blasich | HIV and Mycology | Best Researcher Award

Posted on by ScienceFather

Ms. Nozuko Blasich | HIV and Mycology | Best Researcher Award

Quality Control Technologist, National Health Laboratory Service South Africa

Nozuko Blasich is a Clinical Pathology Medical Technologist specializing in laboratory diagnostics, quality control, and biomedical research. She holds a Master of Science in Biomedical Technology and is currently pursuing a PhD in Biomedical Science, focusing on fungal pathogens and their public health impact. Her research on cryptococcal meningitis has influenced World Health Organization (WHO) policies. She has published in high-impact journals, presented at international conferences, and serves as a peer reviewer. Passionate about improving diagnostic accuracy, she explores point-of-care tests for infectious diseases.

Profile

Orcid

Education 🎓

Nozuko Blasich earned her Master of Science in Biomedical Technology, with research focusing on cryptococcal meningitis, significantly contributing to global health policies. She is currently a PhD candidate in Biomedical Science, investigating fungal pathogens and their environmental prevalence. Her academic journey emphasizes microbiology, clinical diagnostics, and public health.

Experience 🧑‍🏫

She serves as a Quality Control Technologist at the National Health Laboratory Service, ensuring diagnostic accuracy and laboratory efficiency. With expertise in mycology, she has worked extensively on cryptococcal antigen screening and HIV diagnostics.

 Awards & Honors 🏆

She has received recognition for her contributions to medical mycology, including best researcher awards and grants for her impactful studies on fungal pathogens and diagnostic advancements.

Research Interests 🔬

Her research explores fungal infections, laboratory diagnostics, and point-of-care testing to enhance public health interventions. She investigates diagnostic methodologies, antimicrobial resistance, and epidemiology to improve early detection and treatment outcomes.

Publications 📚

  1. Evaluating the Accuracy of Multiple Rapid Diagnostic Tests for HIV Detection in Serum Samples Analysed During Point-of-Care Proficiency Testing Assessments (2025) – Nozuko P. Blasich, Jerom Okot, Artur Ramos, Mduduzi B. Buthelezi, Dumisani F. Shabangu, Mahlatse M. Maleka, Sarvashni Moodliar, Nqobile Ngoma, Tendesayi Kufa

 

  1. Retrospective Assessment of a National Reflex Cryptococcal Antigen Screening Program in South Africa Through Interlaboratory Comparison of Lateral Flow Assay Results (2022) – Nozuko P. Blasich, Lindi M. Coetzee, Charlotte Sriruttan, Daniel DeSanto, Gregory S. Greene, Deborah K. Glencross, Nelesh P. Govender

 

  1. Association of Semi-Quantitative Cryptococcal Antigen Results in Plasma with Subclinical Cryptococcal Meningitis and Mortality Among Patients with Advanced HIV Disease (2021) – Nozuko P. Blasich, Rachel M. Wake, Ivy Rukasha, Yvonne Prince, Nelesh P. Govender

 

  1. Cryptococcus neoformans: Diagnostic Dilemmas, Electron Microscopy and Capsular Variants (2018) – Nozuko P. Blasich, Monica Birkhead, Serisha D. Naicker, Ivy Rukasha, Juno Thomas, Charlotte Sriruttan, Shareef Abrahams, Grisselda S. Mavuso, Nelesh P. Govender

 

Anastasia Kovrizhina | Medicinal chemistry | Women Researcher Award

Posted on by ScienceFather

Dr. Anastasia Kovrizhina | Medicinal chemistry | Women Researcher Award

PhD Reseracher, Tomsk Polytechnic University Russia

Anastasia Kovrizhina is a Russian researcher specializing in organic chemistry and biotechnology. She holds a Ph.D. from National Research Tomsk Polytechnic University, where she focuses on molecular modeling and the synthesis of biologically active compounds. Currently, she is a researcher at Tomsk Polytechnic University and serves as a scientist secretary. Her work includes the development of novel kinase inhibitors and fluorocarbon aza-heterocycles for anticancer treatments. She has been actively involved in international collaborations, including research internships at Montana State University, USA, and Novosibirsk Institute of Organic Chemistry, Russia. With an h-index of 7, she has published extensively in high-impact journals and has presented at numerous international and national conferences. She has received multiple prestigious scholarships and awards, including the Baden-Württemberg State Scholarship and the Government Scholarship of the Russian Federation. Her expertise spans chemical synthesis, biological assays, computational chemistry, and quantum calculations.

Profile

Scopus

Education 🎓

Anastasia Kovrizhina earned her Ph.D. (2019-2023) in Organic Chemistry from National Research Tomsk Polytechnic University, specializing in molecular modeling and drug synthesis. She completed her Master’s degree (2017-2019) in Biotechnology at the same institution, where she studied organic and applied chemistry. During her studies, she participated in an academic exchange at Karlsruhe Institute of Technology, Germany, where she took courses in bioinformatics, bioprocessing, and enzymology. She obtained her Bachelor’s degree (2013-2017) in Biotechnology from National Research Tomsk Polytechnic University, with a strong foundation in chemistry, physics, and humanities. Her academic journey has been complemented by advanced training in computational chemistry, quantum calculations, and SAR/QSAR analysis. She has also gained international exposure through scholarships and research projects focused on innovative drug development. Her multidisciplinary education allows her to integrate experimental and computational approaches for pharmaceutical and medical applications.

Experience 🧑‍🏫

Anastasia Kovrizhina is currently a researcher at Tomsk Polytechnic University, specializing in the synthesis of biologically active compounds. She also serves as a scientist secretary at the School of Advanced Manufacturing Technologies and is an active member of the Council of Young Scientists. She has undertaken research internships at the Novosibirsk Institute of Organic Chemistry (2020) and Montana State University, USA (2019), where she collaborated on immunology and organic chemistry projects. Her work includes grant-funded research on kinase inhibitors, fluorocarbon aza-heterocycles, and polymer scaffolds for cardiovascular applications. She has supervised undergraduate and master’s students and has taught courses in professional English and organic chemistry. Her expertise includes molecular modeling, chemical synthesis, and computational chemistry. She has contributed to multiple research projects under the Russian Science Foundation and has been instrumental in developing innovative drug delivery systems for anticancer treatments.

 Awards & Honors 🏆

Anastasia Kovrizhina has received several prestigious awards, including the First Degree Diploma (2024) for her research on indenoquinoxalinone oxime (IQ-1). She won the 5th All-Russian Research Competition (2020) for her work on indenoquinoxaline derivatives. She was honored with the 3rd Degree Medal for “Achievements for Tomsk Polytechnic University” and the BAYHOST Scholarship for studying German (2020). She received the Baden-Württemberg State Scholarship (2018-2019) and the Russian Government Scholarship (2018-2019). Her participation in international conferences has been recognized with numerous accolades. She has also secured multiple research grants, including the Russian Science Foundation grants for developing kinase inhibitors and fluorocarbon aza-heterocycles as anticancer agents. Her scientific contributions to drug discovery and pharmaceutical chemistry have positioned her as a promising young researcher in her field.

Research Interests 🔬

Anastasia Kovrizhina’s research focuses on the synthesis and molecular modeling of biologically active compounds, particularly kinase inhibitors and fluorocarbon aza-heterocycles for anticancer treatments. She has pioneered the development of JNK kinase inhibitors based on indenoquinoxaline scaffolds, which have potential anti-inflammatory applications. Her work has demonstrated that IQ-1 salts enhance the efficacy of cerebral ischemia treatment. She has conducted pharmacokinetic studies on IQ-1 absorption in the gastrointestinal tract to optimize drug formulation. Her expertise extends to computational chemistry, quantum calculations, and structure-activity relationship (SAR) studies. She is also involved in developing supramolecular complexes for innovative drug delivery. Her interdisciplinary approach integrates synthetic chemistry, computational modeling, and biological assays to advance pharmaceutical research. She has contributed significantly to drug design, molecular docking studies, and the synthesis of novel heterocyclic compounds for targeted therapies.

Publications 📚

  1. Title: 6,8-Dibromo-11H-indeno[1,2-b]quinolin-11-one
    Year: 2024
    Author: Anastasia R. Kovrizhina, Dauren Tolegen, Dmitry I. Pavlov, Andrei S. Potapov, Andrei I. Khlebnikov
    Citations: Not available
    Article: Molbank

 

  1. Title: Evaluation of Nitric Oxide-Donating Properties of 11H-indeno[1,2-b]quinoxalin-11-one Oxime (IQ-1) by Electron Paramagnetic Resonance Spectroscopy
    Year: 2024
    Author: Viacheslav V. Andrianov, Igor A. Schepetkin, Leah V. Bazan, Khalil L. Gainutdinov, Anastasia R. Kovrizhina, Dmitriy N. Atochin, Andrei I. Khlebnikov
    Citations: Not available
    Article: Molecules

 

  1. Title: Dose proportionality and bioavailability of quinoxaline-based JNK inhibitor after single oral and intravenous administration in rats
    Year: 2024
    Author: Galina A. Frelikh, Elena A. Yanovskaya, Alexander P. Lakeev, Galina A. Chernysheva, Vera I. Smolyakova, Anastasia R. Kovrizhina
    Citations: Not available
    Article: Xenobiotica

 

  1. Title: Neuroprotective Effects of Tryptanthrin-6-Oxime in a Rat Model of Transient Focal Cerebral Ischemia
    Year: 2023
    Author: Mark Plotnikov, Galina A. Chernysheva, Vera I. Smol’yakova, Oleg I. Aliev, Anna M. Anishchenko, Olga A. Ulyakhina, Eugene S. Trofimova, Anastasia A. Ligacheva, Nina D. Anfinogenova, Anton Osipenko et al.
    Citations: Not available
    Article: Pharmaceuticals

 

  1. Title: Novel Tryptanthrin Derivatives with Selectivity as c–Jun N–Terminal Kinase (JNK) 3 Inhibitors
    Year: 2023
    Author: Igor A. Schepetkin, Oleksander S. Karpenko, Anastasia R. Kovrizhina, Liliya N. Kirpotina, Andrei I. Khlebnikov, Stepan I. Chekal, Alevtyna V. Radudik, Maryna O. Shybinska, Mark T. Quinn
    Citations: Not available
    Article: Molecules

 

  1. Title: Quantification of a promising JNK inhibitor and nitrovasodilator IQ-1 and its major metabolite in rat plasma by LC–MS/MS
    Year: 2022
    Author: Alexander P. Lakeev, Galina A. Frelikh, Elena A. Yanovskaya, Anastasia R. Kovrizhina, Vladimir V. Udut
    Citations: Not available
    Article: Bioanalysis

 

  1. Title: Poly(ϵ-caprolactone) Scaffolds Doped with c-Jun N-terminal Kinase Inhibitors Modulate Phagocyte Activation
    Year: 2019
    Author: K.S. Stankevich, I.A. Schepetkin, S.I. Goreninskii, A.K. Lavrinenko, E.N. Bolbasov, A.R. Kovrizhina, L.N. Kirpotina, V.D. Filimonov, A.I. Khlebnikov, S.I. Tverdokhlebov et al.
    Citations: Not available
    Article: ACS Biomaterials Science and Engineering

 

Srijan Acharya | Molecular Pharmacology | Excellence in Research

Posted on by ScienceFather

Dr. Srijan Acharya | Molecular Pharmacology | Excellence in Research

Dr at St. Jude Children’s Research Hospital, United States

Srijan Acharya is a dedicated scientist with expertise in molecular pharmacology and cancer genomics. He is currently a Post-Doctoral Research Fellow at St. Jude Children’s Research Hospital, focusing on childhood cancer research. With 32 published scientific articles and a total citation count of over 385, his work has contributed significantly to biomarker discovery, receptor pharmacology, and immuno-oncology. His research aims to address therapeutic resistance in pediatric malignancies through small molecule screening. Srijan is fluent in English, Bangla, and Hindi, with basic knowledge of Korean.

Profile

Scholar

🎓 Education

PhD in Molecular Pharmacology from Chonnam National University, South Korea (2020). M.Sc. in Biotechnology from North South University, Bangladesh (2015). BPHRM in Pharmacy from East West University, Bangladesh (2012). His academic journey has provided a strong foundation in receptor pharmacology and molecular biology, guiding his transition into cancer research.

💼 Experience

Post-Doctoral Research Fellow, Pharmacy Department, St. Jude Children’s Research Hospital, USA (2023-Present). Post-Doctoral Research Fellow, Pathology Department, Mitchell Cancer Institute, USA (2020-2023). Executive Officer, Research and Development, Square Pharmaceutical PLC, Bangladesh (2012-2013). His experience spans academia and industry, with a focus on cancer research, receptor signaling, and small molecule screening.

🏆 Awards and Honors

Inducted into Sigma Xi, The Scientific Research Honor Society (2023). Recognized in Who’s Who in America by Marquis (2023). Young Investigator Award at AACR conference by AAISCR (2022). Best Presenter Award from China Pharmaceutical University (2021). Global Scholarship from Chonnam National University, Korea (2015). These accolades reflect his significant contributions to molecular pharmacology and cancer research.

🔬 Research Focus

Srijan’s research primarily investigates the role of molecular signaling in cancer, focusing on the interaction of nicotine receptors with GPCRs and their impact on cancer progression. At St. Jude, his work focuses on childhood cancers, particularly Ewing sarcoma and rhabdomyosarcoma. He uses small molecule screening to discover potential therapeutic agents and aims to overcome therapeutic resistance in pediatric cancers.

Conclusion

Srijan Acharya is a highly accomplished and promising researcher whose contributions to cancer pharmacology and molecular biology are noteworthy. His interdisciplinary research approach, combined with his dedication to advancing pediatric oncology, positions him as a leader in the field. With continued mentorship and broader collaborative efforts, Acharya is well poised for even greater achievements, further solidifying his place as an influential scientist in the biomedical community.

📚Publications 

  • Title: Unveiling the intracellular dynamics of α4β2 nAChR-mediated ERK activation through the interplay of arrestin, Gβγ, and PKCβII
    Year: 2024
    Authors: Dooti K, Acharya S, Wang S, Kim K.M.

 

  • Title: Biphasic transcriptional and posttranscriptional regulation of MYB by androgen signaling mediates its growth control in prostate cancer
    Year: 2023
    Authors: Acharya S, Anand S, Khan MA, Zubair H, Srivastava SK, Singh S, Singh AP

 

  • Title: MYB exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer
    Year: 2023
    Authors: Md Khan, S Acharya, S Anand, F Sameeta, P Pramanik, C Keel, S Singh, James E Carter, S Dasgupta, A Singh

 

  • Title: Comparative study of the molecular mechanisms underlying the G protein and β-arrestin-dependent pathways that lead to ERKs activation upon stimulation by dopamine D2 receptor
    Year: 2023
    Authors: Liu H, Acharya S, Sudan SK, Hu L, Wu C, Cao Y, Li H, Zhang X

 

  • Title: Frequent loss of cacna1c, a calcium voltage-gated channel subunit is associated with lung adenocarcinoma progression and poor prognosis
    Year: 2023
    Authors: Dasgupta, S., Acharya, S., Khan, M. A., Pramanik, P., Marbut, S. M., Yunus, F., Galeas, J. N., Singh, S., Singh, A. P., and Dasgupta, S.

 

  • Title: Nicotine causes alternative polarization of macrophages via Src-mediated STAT3 activation: Potential pathobiological implications
    Year: 2022
    Authors: Acharya S, Saranyutanon S, Deshmukh SK, Khan MA, Singh S, Singh AP

 

  • Title: β-Arrestin1 and GRK2 play permissive roles in Src-mediated endocytosis of α4β2 nicotinic acetylcholine receptor
    Year: 2021
    Authors: Acharya S, Kundu D, Kim KM

 

  • Title: Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease
    Year: 2021
    Authors: Acharya S, Kim KM

 

  • Title: Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer
    Year: 2021
    Authors: Miree, O., Srivastava, …Acharya S.et al.

 

  • Title: Metabotropic signaling cascade involved in α4β2 nicotinic acetylcholine receptor-mediated PKCβII activation
    Year: 2020
    Authors: Acharya S, D. Kundu, H.J. Choi, and K.M. Kim

 

  • Title: Catalpol and Mannitol, Two Components of Rehmannia glutinosa, Exhibit Anticonvulsant Effects Probably via GABAA Receptor Regulation
    Year: 2019
    Authors: Acharya S, Kim M., Botanas C. J., Custodio R. J., Lee H. J., Sayson L. V., Kim H. J.

 

  • Title: Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors
    Year: 2017
    Authors: Paudel S, Acharya S, Yoon G, Kim K.M., & Cheon S.H.